Cuál es el precio por Algernon Pharmaceuticals Inc. (AGN)

Precio por Algernon Pharmaceuticals Inc. (AGN) es de$0.29357476

Cuál es la capitalización de mercado por Algernon Pharmaceuticals Inc. (AGN)

Capitalización de mercado por Algernon Pharmaceuticals Inc. (AGN) es $1.02M

Algernon Pharmaceuticals Inc. (AGN) Margen Operativo

Algernon Pharmaceuticals Inc. is a clinical-stage pharmaceutical company dedicated to discovering and developing new treatments. Their research and development efforts concentrate on a range of serious conditions, including non-alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19, operating across Canada and Australia. The company's primary drug candidate, NP-120, acts as an N-methyl-d-aspartate (NMDA) receptor glutamate antagonist. This compound specifically targets the NMDA-type subunit 2B (Glu2NB) and also demonstrates agonist activity for the Sigma-1 receptor, a chaperone protein elevated during endoplasmic reticulum stress. Furthermore, Algernon is advancing AP-188, a psychedelic agent from the tryptamine family, for treating ischemic stroke in humans. Preclinical investigations for AP-188, as part of their stroke clinical research program, are underway through a collaboration with Charles River Laboratories. Established in 2015, Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.

Año	Margen Operativo	Cambiar
Not enough data for the provided dates.

Año

Margen Operativo

Cambiar

Not enough data for the provided dates.

Empresa	Margen Operativo	Diferencia de Margen Operativo	País
Vertex Pharmaceuticals Incorporated VRTX.US	38.97%	-	US
Argenx SE ARGX.US	28.81%	-	NL
Lonza Group AG LONN.SW	0.00%	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0.00%	-	KR
UCB S.A. UCB.BR	31.23%	-	BE

Empresa

Margen Operativo

Diferencia de Margen Operativo

País